Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs First Solar, Inc. (FSLR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs First Solar, Inc. — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $296.35 (market cap $8.04B), while First Solar, Inc. trades at $224.71 (market cap $23.70B). The key difference: First Solar, Inc. is far larger — about 2.9× Bio-Rad Laboratories, Inc. Class A Common Stock's market cap, and Bio-Rad Laboratories, Inc. Class A Common Stock is trading nearer its 52-week high, First Solar, Inc. nearer its low. Which is the better fit depends on your goals.
| BIO | FSLR | |
|---|---|---|
Market Cap | $8.04B | $23.70B |
Sector | Health | Technology |
52-Week High | $339.75 | $318.30 |
52-Week Low | $241.71 | $166.82 |
Enterprise Value | $7.85B | $21.86B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $297.58, up 0.5% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $305. The stock shows strong profitability with a 51.87% gross margin and positive net income of $760M in 2025, though recent quarters have seen EPS misses. Cash flow from operations remains robust at $532M, supporting financial stability.
Outlook is cautiously optimistic with analyst support, but risks include earnings volatility and high P/E valuation. The company's return to profitability and solid balance sheet provide a foundation for growth, though investors should monitor execution against future earnings expectations and competitive pressures in the biotech sector.
First Solar (FSLR) trades at $221.03, down 2.98% on the day, amid bearish technical signals and multiple class-action lawsuit announcements. The stock shows strong fundamentals with a P/E of 14.28, net income margin of 30.73%, and robust cash flow growth, but recent earnings misses and legal overhangs weigh on sentiment. Analyst consensus remains bullish with a $275.17 price target, highlighting a disconnect between near-term headwinds and long-term growth prospects in the solar energy sector.
The outlook for FSLR balances solid financial health and analyst optimism against significant litigation risks and technical weakness. Investment opportunity lies in its profitability and sector tailwinds, but investors face volatility from legal proceedings and market sentiment pressures. Careful monitoring of lawsuit developments and quarterly earnings is essential for navigating the stock's near-term trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About First Solar, Inc.
First Solar designs and manufactures solar photovoltaic panels, modules, and systems for use in utility-scale development projects. The company's solar modules use cadmium telluride to convert sunlight into electricity. This is commonly called thin-film technology. First Solar is the world's largest thin-film solar module manufacturer. It has production lines in Vietnam, Malaysia, the United States, and a new factory under construction in India.
Read more on FSLR →
